New Pathway Identified: Splenic Tr1 Cells Drive Transplant Tolerance via Areg–EGFR Signaling
January 8, 2026
Brand Name :
Vicineum
Synonyms :
oportuzumab monatox
Class :
Antineoplastics, Monoclonal Antibody
Actions and Spectrum:
None
Frequency defined
None
Black Box Warning:
None
Pregnancy warnings:
Pregnancy category: N/A
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
None
Pharmacodynamics
None
Pharmacokinetics
Absorption, Distribution, Metabolism and Elimination and Excretion not known for oportuzumab monatox drug.
Administration
oportuzumab monatox is an antibody-drug conjugate that is administered intravenously.
Patient information leaflet
Generic Name: oportuzumab monatox (Pending FDA Approval)
Why do we use oportuzumab monatox?
oportuzumab monatox is an antibody-drug conjugate that combines an anti-epithelial cell adhesion molecule (EpCAM) antibody with a toxin called Pseudomonas exotoxin A.
oportuzumab monatox is designed to target and bind to EpCAM, a protein that is often overexpressed in urothelial carcinoma cells and deliver the toxin to kill the cancer cells.